HNRNPA1 Protein

HNRNPA1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">HNRNPA1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HNRNPA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HNRNPA1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=HNRNPA1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">222 edges</a></td>
</tr>
</table>

Pathway Diagram

HNRNPA1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">HNRNPA1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HNRNPA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HNRNPA1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=HNRNPA1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">222 edges</a></td>
</tr>
</table>

Pathway Diagram

Path: proteins/hnrnpa1-protein Title: HNRNPA1 Protein Tags: section:proteins, kind:protein, topic:rna-binding-protein, topic:als, topic:ftd, topic:stress-granules

Overview

Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) is a multifunctional RNA-binding protein that plays critical roles in RNA metabolism, including alternative splicing, mRNA stability, transcription regulation, and telomere maintenance[@dreyfuss2002]. HNRNPA1 is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, which comprises abundant nuclear proteins that bind pre-mRNA and facilitate various aspects of RNA processing[@han2010]. In the nervous system, HNRNPA1 is essential for neuronal development, synaptic function, and overall RNA homeostasis[@bolognani2008].

Mutations in the HNRNPA1 gene have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two related neurodegenerative disorders characterized by the progressive loss of motor [neurons](/entities/neurons) or frontal/temporal cortical neurons, respectively[@kim2013]. HNRNPA1 is increasingly recognized as a key player in the molecular mechanisms underlying these diseases, particularly through its involvement in stress granule formation, RNA metabolism dysregulation, and pathological protein aggregation[@li2013]. Understanding the normal functions of HNRNPA1 and how disease-causing mutations disrupt these functions is essential for developing therapeutic interventions for ALS and related disorders.

Protein Structure and Domains

Primary Structure

HNRNPA1 is encoded by the HNRNPA1 gene located on chromosome 12q13.13 in humans[@biamonti1994]. The protein consists of 372 amino acids with a molecular weight of approximately 38 kDa[@swanson1987]. The primary amino acid sequence contains multiple functional domains that mediate its diverse biological activities.

Domain Organization

HNRNPA1 possesses a modular domain architecture consisting of two RNA recognition motifs (RRMs) connected by a linker region, flanked by an N-terminal low-complexity domain (LCD) and a C-terminal glycine-rich region[@mayeda1994]. Each RRM contains the highly conserved RNP-1 and RNP-2 motifs, which are essential for RNA binding specificity and affinity[@burd1994].

RNA Recognition Motif 1 (RRM1): Located at residues 106-177, this domain exhibits high affinity for single-stranded RNA sequences containing UAG, UAA, and UGA motifs[@gorlach1994]. The RRM1 domain is primarily responsible for the sequence-specific binding of HNRNPA1 to target mRNAs.

RNA Recognition Motif 2 (RRM2): Spanning residues 183-259, the RRM2 domain contributes to RNA binding but with different sequence preferences than RRM1[@shamoo1997]. The two RRMs often cooperate to enhance binding specificity and affinity for complex RNA structures.

Low-Complexity Domain (LCD): The N-terminal LCD (residues 1-186) contains multiple glycine, phenylalanine, and serine residues and is involved in protein-protein interactions and phase separation[@kato2012]. This domain is particularly important for the formation of stress granules and other membrane-less organelles through liquid-liquid phase separation (LLPS).

C-terminal Glycine-Rich Region: This region (residues 320-372) mediates interactions with other hnRNP proteins and contributes to the formation of higher-order protein assemblies[@cartegni1996].

Post-Translational Modifications

HNRNPA1 undergoes various post-translational modifications that regulate its activity, subcellular localization, and protein-protein interactions. Key modifications include:

Phosphorylation: HNRNPA1 is phosphorylated at multiple serine and threonine residues by various kinases, including protein kinase C (PKC), casein kinase 2 (CK2), and mitogen-activated protein kinases (MAPKs)[@idler2012]. Phosphorylation can modulate RNA binding affinity, alter subcellular localization, and affect interaction with partner proteins.

Methylation: Arginine methylation of HNRNPA1 by protein arginine methyltransferases (PRMTs) regulates its interactions with other RNA-binding proteins and affects alternative splicing patterns[@cheng2021].

Acetylation: Lysine acetylation of HNRNPA1 has been reported and may influence protein stability and function[@yang2018].

Normal Biological Functions

RNA Processing

HNRNPA1 participates in multiple aspects of RNA metabolism, making it essential for cellular homeostasis:

Alternative Splicing: HNRNPA1 is a well-characterized splicing regulator that promotes exon skipping and alternative splice site selection[@caceres1994]. It competes with splicing factors for binding to regulatory sequences in pre-mRNA and can influence spliceosome assembly. HNRNPA1-mediated splicing decisions affect numerous neuronal genes, including those involved in synaptic function and neuronal development[@licatalosi2006].

mRNA Stability and Translation: By binding to specific sequences in the 3' untranslated regions (UTRs) of target mRNAs, HNRNPA1 can either stabilize or destabilize transcripts[@hamilton2013]. HNRNPA1 also influences translation efficiency by interacting with translation initiation factors and ribosomal components[@svitkin2013].

Transcriptional Regulation: HNRNPA1 can shuttle between the nucleus and cytoplasm and participates in transcriptional regulation by interacting with transcription factors and chromatin-associated proteins[@oneill2019].

Telomere Maintenance: HNRNPA1 binds to telomeric DNA and contributes to telomere length regulation and protection[@zhang2006].

Stress Granule Formation

One of the most biologically significant functions of HNRNPA1 is its involvement in stress granule (SG) formation. Stress granules are membrane-less organelles that form in the cytoplasm in response to various cellular stresses, including oxidative stress, heat shock, viral infection, and endoplasmic reticulum stress[@anderson2008].

Mechanism of Incorporation: During stress, HNRNPA1 translocates from the nucleus to the cytoplasm and becomes incorporated into stress granules through its low-complexity domain-mediated interactions[@guil2006]. The LCD enables HNRNPA1 to undergo liquid-liquid phase separation, driving the formation of stress granules.

SG Dynamics: HNRNPA1-containing SGs are dynamic structures that continuously exchange components with the cytoplasm. The protein exhibits liquid-like behavior within SGs, with relatively rapid on-off kinetics[@kedersha2008]. This dynamic nature is thought to be important for the protective function of SGs.

Physiological Significance: Stress granules serve as temporary storage sites for translationally arrested mRNAs and associated proteins, allowing cells to conserve resources during stress and prioritize stress response pathways[@protter2016]. By sequestering certain mRNAs and proteins, SGs also influence which cellular programs are active during stress recovery.

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive neurodegenerative disease characterized by the selective loss of upper and lower motor neurons. HNRNPA1 mutations cause familial ALS and contribute to disease pathogenesis through multiple mechanisms[@liu2015].

Disease-Causing Mutations: Multiple HNRNPA1 mutations have been identified in patients with familial ALS, including p.D262V, p.G288V, p.P298L, and p.M310I[@bampton2020]. These mutations are predominantly located in the low-complexity domain and alter the phase separation properties of the protein.

Mutant HNRNPA1 in Stress Granules: ALS-associated HNRNPA1 mutations affect stress granule dynamics. Mutant proteins exhibit altered SG localization, increased tendency to form cytoplasmic inclusions, and impaired SG disassembly[@kim2013a]. This dysfunction may lead to the persistence of stress granules and subsequent pathological aggregation.

[TDP-43](/mechanisms/tdp-43-proteinopathy) Pathology: HNRNPA1 interacts with TDP-43 (TAR DNA-binding protein 43), another RNA-binding protein that forms characteristic cytoplasmic inclusions in ALS[@lagiertourenne2010]. Both proteins co-localize in stress granules, and HNRNPA1 mutations may contribute to TDP-43 mislocalization and aggregation.

Gain-of-Toxicity: Current evidence suggests that HNRNPA1 mutations cause disease through a gain-of-toxicity mechanism rather than loss of normal function[@harrison2017]. Mutant HNRNPA1 may form toxic oligomers or aggregates that disrupt cellular homeostasis.

Frontotemporal Dementia (FTD)

FTD encompasses a group of neurodegenerative disorders characterized by progressive deficits in behavior, language, and executive function due to frontal and temporal cortical degeneration[@rascovsky2011]. HNRNPA1 mutations have been identified in patients with FTD, particularly in cases with overlapping ALS pathology[@benussi2021].

FTD Subtypes: HNRNPA1 mutations are associated with both behavioral variant FTD (bvFTD) and primary progressive aphasia (PPA)[@rohrer2011]. The clinical phenotype depends on the pattern and extent of cortical involvement.

Relationship with ALS: There is significant clinical and pathological overlap between ALS and FTD, and HNRNPA1 mutations can cause either disease alone or the ALS-FTD spectrum disorder[@ferrari2011]. This underscores the shared molecular mechanisms between these conditions.

Other Neurodegenerative Disorders

Inclusion Body Myopathy with Paget Disease of Bone (IBMPFD): HNRNPA1 mutations were first identified in patients with IBMPFD, a disorder characterized by muscle weakness, bone abnormalities, and frontotemporal dementia[@kim2014]. This provided the initial link between HNRNPA1 and neurodegenerative disease.

Multisystem Proteinopathy (MSP): HNRNPA1 is now recognized as a cause of multisystem proteinopathy, a syndrome involving combinations of ALS, FTD, IBMPFD, and other features[@taylor2014].

Molecular Mechanisms of Pathogenesis

Dysregulated Phase Separation

The low-complexity domain of HNRNPA1 enables liquid-liquid phase separation, and disease-causing mutations alter this property[@molliex2015]. Mutations can:

Promote Solidification: Some mutations increase the propensity of HNRNPA1 to form more solid-like assemblies, potentially leading to irreversible aggregation[@murakami2015].

Increase Aggregation Tendency: Mutant HNRNPA1 shows enhanced aggregation in cellular models and in vitro assays[@liu2021].

Alters SG Dynamics: Mutations affect the exchange rate of HNRNPA1 between SGs and the cytoplasm, potentially impairing SG function[@wang2018].

RNA Metabolism Dysregulation

HNRNPA1 mutations disrupt normal RNA metabolism through multiple mechanisms:

Altered Splicing Patterns: Mutant HNRNPA1 causes aberrant alternative splicing of neuronal genes, potentially disrupting synaptic function and neuronal viability[@liu2016].

mRNA Transport Defects: HNRNPA1 is involved in dendritic mRNA transport and local translation at synapses. Mutations may impair these processes[@glisovic2008].

Transcriptomic Changes: Global transcriptomic analyses reveal widespread mRNA expression changes in cells expressing mutant HNRNPA1[@yu2022].

Proteostasis Disruption

Impaired [Autophagy](/entities/autophagy): Mutant HNRNPA1 may be poorly cleared by cellular protein quality control systems, including autophagy and the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system)[@buchan2013].

Interactions with Other Aggregation-Prone Proteins: HNRNPA1 interacts with other disease-related proteins, including TDP-43, FUS, and [C9orf72](/entities/c9orf72), potentially promoting co-aggregation[@conicella2016].

Therapeutic Approaches

Targeting HNRNPA1 Aggregation

Small Molecule Inhibitors: Compounds that prevent HNRNPA1 aggregation or promote clearance are being investigated[@fang2019]. These include molecules that modulate phase separation behavior.

Peptide-Based Approaches: Designer peptides that interfere with HNRNPA1 aggregation pathways are under development[@zhang2020].

Modulating Stress Granule Dynamics

SG Modulators: Compounds that normalize stress granule formation and dissolution may be beneficial[@siddegowda2021]. This includes kinase inhibitors that regulate SG formation.

Autophagy Enhancers: Drugs that enhance autophagy may help clear mutant HNRNPA1 and prevent accumulation[@barmada2014].

Gene Therapy Approaches

Antisense Oligonucleotides (ASOs): ASOs targeting HNRNPA1 mRNA could reduce expression of mutant protein[@smith2022]. However, this approach must balance reducing toxic mutant protein while maintaining sufficient normal HNRNPA1 function.

CRISPR-Based Therapies: Gene editing approaches to correct disease-causing mutations are being explored[@gaj2017].

Research Tools and Models

Cellular Models

Cell Lines: Inducible cell lines expressing wild-type and mutant HNRNPA1 are used to study disease mechanisms[@broom2015].

Neuronal Cultures: Primary neuron cultures and induced pluripotent stem cell (iPSC)-derived neurons provide disease-relevant models[@sareen2013].

Animal Models

Transgenic Mice: Mouse models expressing mutant HNRNPA1 recapitulate aspects of ALS/FTD pathology[@peters2015].

Drosophila Models: Fruit fly models allow rapid screening of genetic modifiers and therapeutic compounds[@casci2014].

Biomarker Potential

Diagnostic Biomarkers

CSF HNRNPA1: Cerebrospinal fluid levels of HNRNPA1 are being evaluated as a potential diagnostic biomarker for ALS/FTD[@verdone2022].

Autoantibodies: HNRNPA1 autoantibodies have been detected in some patients and may serve as biomarkers[@fekihmrissa2017].

Disease Progression Markers

Phosphorylated HNRNPA1: Specific post-translational modifications of HNRNPA1 may indicate disease progression[@chen2019].

Conclusion

HNRNPA1 is a critical RNA-binding protein with diverse functions in RNA metabolism and stress response. Its role in ALS and FTD pathogenesis has become increasingly clear, with disease-causing mutations affecting stress granule dynamics, RNA processing, and protein homeostasis. Understanding the molecular mechanisms by which HNRNPA1 mutations cause neurodegeneration provides insights into disease pathogenesis and identifies potential therapeutic targets. Continued research on HNRNPA1 and its interactions with other disease-related proteins will be essential for developing effective treatments for ALS, FTD, and related disorders.

See Also

• [TDP-43](/mechanisms/tdp-43-proteinopathy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References